 NEW YORK, Nov. 11, 2020 GLOBE NEWSWIRE -- Mesoblast Limited Nasdaq: MESO; ASX: MSB today announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with moderate to severe acute respiratory distress syndrome ARDS due to COVID-19 infection had received a recommendation to continue from the independent Data Safety Monitoring Board DSMB following completion of the trials second interim analysis. The analysis was performed on the trials first 135 patients, 45 of the total target of up to 300 randomized patients, with the DSMB recommending continuation after reviewing the trials primary endpoint, all-cause mortality within 30 days of randomization and all safety data. The key secondary endpoint is days alive off mechanical ventilatory support within 60 days of randomization. 